Valsts: Īrija
Valoda: angļu
Klimata pārmaiņas: HPRA (Health Products Regulatory Authority)
POLY(O-2-HYDROXYETHYL)STARCH, SODIUM CHLORIDE, POTASSIUM CHLORIDE, CALCIUM CHLORIDE DIHYDRATE, MAGNESIUM CHLORIDE HEXAHYDRATE, SODIUM ACETATE TRIHYDRATE, L-MALIC ACID DAB
B. Braun Melsungen AG
B05AA07
POLY(O-2-HYDROXYETHYL)STARCH, SODIUM CHLORIDE, POTASSIUM CHLORIDE, CALCIUM CHLORIDE DIHYDRATE, MAGNESIUM CHLORIDE HEXAHYDRATE, S
60 Mg/Ml
Solution for Infusion
Product subject to prescription which may not be renewed (A)
Blood substitutes and plasma protein fractions
Authorised
2007-01-26
PACKAGE LEAFLET: INFORMATION FOR THE USER EQUIHES 60 MG/ML SOLUTION FOR INFUSION ECOFLAC PLUS ® This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects. READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. _● _Keep this leaflet. You may need to read it again. _● _If you have any further questions, ask your doctor, nurse or pharmacist. _● _This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. _● _If you get any side effects, talk to your doctor, nurse or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What EquiHes 60 mg/ml is and what it is used for 2. What you need to know before you use EquiHes 60 mg/ml 3. How to use EquiHes 60 mg/ml 4. Possible side effects 5. How to store EquiHes 60 mg/ml 6. Contents of the pack and other information 1. WHAT EQUIHES 60 MG/ML IS AND WHAT IT IS USED FOR EquiHes 60 mg/ml is an infusion solution which is administered via a cannula into a vein. EquiHes 60 mg/ml is a plasma volume substitute that is used to restore the blood volume when you have lostblood when other products called crystalloids are not considered sufficient alone. 2. WHAT YOU NEED TO KNOW BEFORE YOU USE EQUIHES 60 MG/ML DO NOT USE EQUIHES 60 MG/ML IF YOU: are allergic to any of the active substances or any of the other ingredients of this medicine (listed in section 6). suffer from serious generalised infection (sepsis Izlasiet visu dokumentu
SUMMARY OF PRODUCT CHARACTERISTICS This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1 NAME OF THE MEDICINAL PRODUCT EquiHes 60 mg/ml solution for infusion, Ecoflac Plus 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1000 ml contains: _Electrolyte concentration:_ For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Solution for infusion. Clear, colourless, aqueous solution pH: 5.6 6.4 Theoretical osmolarity: 296 mOsmol/l Acidity (titration to pH 7.4): <2.0 mmol/l 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of hypovolaemia due to acute blood loss when crystalloids alone are not considered sufficient. (see sections 4.2, 4.3 and 4.4). Hydroxyethyl starch (HES) 60.0g (Molar substitution: 0.42) (Average molecular weight: 130,000Da) Sodium chloride 6.25g Potassium chloride 0.30g Calcium chloride dihydrate 0.37g Magnesium chloride hexahydrate 0.20g Sodium acetate trihydrate 3.27g L-Malic acid 0.67g Sodium 140 mmol/l Potassium 4.0 mmol/l Calcium 2.5 mmol/l Magnesium 1.0 mmol/l Chloride 118 mmol/l Acetate 24 mmol/l L-Malate 5.0 mmol/l H E A L T H P R O D U C T S R E G U L A T O R Y A U T H O R I T Y ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ _D_ _a_ _t_ _e_ _ _ _P_ _r_ _i_ _n_ _t_ _e_ _d_ _ _ _2_ _3_ _/_ _0_ _1_ _/_ _2_ _0_ _1_ _8_ _C_ _R_ _N_ _ _ _2_ _1_ _9_ _5_ _6_ _9_ _7_ _p_ _a_ _g_ _e_ _ _ _n_ _u_ _m_ _b_ _e_ _r_ _:_ _ _ _1_ 4.2 POSOLOGY AND METHOD OF ADMINISTRATI Izlasiet visu dokumentu